Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
Rchr
J-GLOBAL ID：202001002814916935
Update date: Mar. 04, 2025 Sato Yasuyoshi
サトウ ヤスヨシ | Sato Yasuyoshi
The University of Tokyo Hospital Department of Clinical Oncology
About The University of Tokyo Hospital Department of Clinical Oncology
Job title： Project Assistant Professor
Other affiliations (1)：
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Medical Oncology Adjunct Physician
- 2020 - 2023 肉腫における腫瘍内免疫応答の解析に基づく最適な複合的免疫療法の検討
- TR・アカデミア創薬人材育成プログラム
- Tetsuya Urasaki, Makiko Ono, Kyoko Yamashita, Taisuke Tanizawa, Yuki Togashi, Akihiro Ohmoto, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Takehiro Nakao, et al. Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal EWSR1::NFATC2 sarcoma: A case report. Oncology letters. 2025. 29. 3. 108-108
- Kazunaga Ishigaki, Yurie Tokito, Naminatsu Takahara, Hiroto Nishio, Go Endo, Koshiro Fukuda, Kota Ishida, Rintaro Fukuda, Shinya Takaoka, Hiroki Oyama, et al. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database. Journal of gastroenterology. 2025. 60. 2. 247-256
- Kenji Nakano, Naomi Hayashi, Xiofei Wang, Akihiro Ohmoto, Tetsuya Urasaki, Naoki Fukuda, Yasuyoshi Sato, Makiko Ono, Junichi Tomomatsu, Mayu Yunokawa, et al. Gemcitabine-Based Chemotherapy for Advanced Soft Tissue Sarcoma: Identifying the Appropriate Dose and Schedule. Cureus. 2024. 16. 12. e76149
- Yasuyoshi Sato, Kazuhiko Mori, Shinichiro Atsumi, Kei Sakamoto, Shuichiro Oya, Asami Okamoto, Masayuki Urabe, Yoshiyuki Miwa, Shoh Yajima, Koichi Yagi, et al. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute. Esophagus. 2024. 21. 4. 514-522
- YASUYOSHI SATO, HIROHARU YAMASHITA, KOICHI YAGI, SACHIYO NOMURA, YASUYUKI SETO. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial. Anticancer Research. 2024. 44. 7. 3125-3131
- 佐藤 靖祥. 【ゲノム医学を外科診療に活かす!】癌種別・ゲノム情報の治療選択への活用 胃癌. 臨床外科. 2024. 79. 2. 172-176
- 佐藤 靖祥, 瀬戸 泰之. 【外科医が知っておくべき! 免疫チェックポイント阻害薬】症例紹介 腹水濾過濃縮再静注法(CART)を併用してニボルマブ療法を行いCRが得られた高度腹水を伴う胃癌症例. 臨床外科. 2023. 78. 1. 70-72
- 八木 浩一, 佐藤 靖祥, 李 基成, 谷島 翔, 奥村 康弘, 平野 康介, 若松 高太郎, 愛甲 丞, 山下 裕玄, 野村 幸世, et al. 【外科医のための-悪性腫瘍補助療法のすべて】食道癌の術前補助療法. 臨床外科. 2021. 76. 2. 154-159
- 佐藤 靖祥. 【消化器領域における免疫チェックポイント阻害薬の現状・今後の展望】免疫チェックポイント阻害薬の臨床効果予測 バイオマーカー開発の現状. 臨床消化器内科. 2020. 35. 5. 487-493
- 佐藤 靖祥. 【免疫チェックポイント阻害薬-押さえるべき特徴と注意点】免疫チェックポイント阻害薬とバイオマーカー. 臨床検査. 2020. 64. 1. 20-25
-
食道癌のNivolumab療法における予後予測因子としての炎症栄養学的指標の検討
(日本食道学会学術集会プログラム・抄録集 2024) -
切除不能進行・食道癌に対するNivolumab単剤療法におけるリンパ節転移の影響
(日本食道学会学術集会プログラム・抄録集 2024) -
A potential novel therapeutic target for invasive soft tissue sarcoma detected through tumor immune microenvironment and genetic profile analyses.
(Journal of Clinical Oncology 2024) -
甲状腺乳頭癌へのレンバチニブ療法におけるBRAF変異の影響 C-CATデータベースによる検討
(頭頸部癌 2024) -
切除不能進行・再発胃癌に対するNivolumab単剤療法におけるリンパ節転移の影響
(日本胃癌学会総会記事 2024)
- 2015 - 2019 The University of Tokyo Graduate School of Medicine
- - 2008 Chiba University School of Medicine
- 2024/02 - 現在 The University of Tokyo Hospital Department of Clinical Oncology Project Assistant Professor
- 2023/04 - 2025/03 The Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Medical Oncology Adjunct Physician
- 2023/04 - 2024/01 The University of Tokyo Hospital Department of Chemotherapy / Cancer Center Project Assistant Professor
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
